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Isocitrate dehydrogenase (IDH) mutations are frequent in
blast-phase myeloproliferative neoplasms and might therefore
contribute to leukemic transformation. We examined this
possibility in 301 consecutive patients with chronic-phase
primary myeloﬁbrosis (PMF). The mutant IDH was detected in
12 patients (4%): 7 IDH2 (5 R140Q, 1 R140W and 1 R172G) and
5 IDH1 (3 R132S and 2 R132C). In all, 6 (50%) of the 12
IDH-mutated patients also expressed JAK2V617F. Overall,
18 (6%) patients displayed only MPL and 164 (54.3%) only
JAK2 mutations. Multivariable analysis that accounted for
conventional risk factors disclosed inferior overall survival
(OS; P¼0.03) and leukemia-free survival (LFS; P¼0.003) in
IDH-mutated patients: OS hazard ratio (HR) was 0.39 (95%
conﬁdence interval (95% CI) 0.2–0.75), 0.50 (95% CI 0.27–0.95)
and 0.53 (95% CI 0.23–1.2) for patients with no, JAK2 or MPL
mutations, respectively. Further analysis disclosed a more
pronounced effect for the mutant IDH on OS and LFS in the
presence (P¼0.0002 and Po0.0001, respectively) as opposed
to the absence (P¼0.34 and P¼0.64) of concomitant
JAK2V617F. Analysis of paired samples obtained during
chronic- and blast-phase disease revealed the presence of
both IDH and JAK2 mutations at both time points. Our
observations suggest that IDH mutations in PMF are indepen-
dent predictors of leukemic transformation and raise the
possibility of leukemogenic collaboration with JAK2V617F.
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published online 13 September 2011
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Introduction
Among the three BCR-ABL1-negative myeloproliferative neo-
plasms (MPNs), including polycythemia vera, essential throm-
bocythemia and primary myeloﬁbrosis (PMF), the latter is by
far the worst in terms of both survival and quality of life.
1,2
The more aggressive disease biology in PMF is also manifest by
the higher prevalence of cytogenetic abnormalities
3 and somatic
mutations.
4 The latter involve JAK2, MPL, TET2, ASXL1, CBL,
isocitrate dehydrogenase (IDH)1, IDH2, IKZF1, LNK, EZH2 and
DNMT3A.
4,5 Recent studies have reported higher frequencies of
IDH1/IDH2 and LNK mutations in blast-phase MPN,
6,7 suggest-
ing a pathogenetic contribution to disease progression.
Isocitrate dehydrogenase-1 is located on chromosome 2q33.3
and IDH2 on chromosome 15q26.1. Both genes encode
enzymes that catalyze oxidative decarboxylation of isocitrate to
a-ketoglutarate. IDH mutations involve exon 4 and affect three
speciﬁc arginine residues: R132 (IDH1), R172 (IDH2) and R140
(IDH2).
8 The mutant IDH has decreased afﬁnity for isocitrate
but displays catalytic activity in converting a-ketoglutarate to
2-hydroxyglutarate.
9–12 Decreased supply of a-ketoglutarate or
accumulation of 2-hydroxyglutarate is believed to underlie the
oncogenic properties of the mutant IDH.
9,13
IDH mutations are prevalent in low-grade gliomas and secondary
glioblastomas (mutational frequency B70%)
14 and they have
also been described, although at a much lower frequency, in
myeloid malignancies including acute myeloid leukemia (AML;
10–20%),
15–18 myelodysplastic syndrome (MDS; 3–5%),
19,20 MPN
(1–4%),
8,18 MDS/MPN including chronic myelomonocytic leukemia
(B9%),
20 post-MDS AML (B15%),
19 post-MPN AML (B22%),
8
post-MDS/MPN AML (B10%),
20 del(5q)-associated high-risk MDS
or AML (B22%)
21 and blast-phase chronic myelogenous leukemia
(B4%).
22 Single case reports also included angioimmunoblastic
lymphoma
23 and acute lymphoblastic leukemia.
18
Several studies have examined the phenotypic and prognostic
effects of both IDH1 and IDH2 mutations in AML, and most have
shown a consistent association with normal or intermediate-risk
karyotype, sole trisomy 8 and NPM1 mutations.
16,17,23–27 The
mutant IDH1 was associated with worse prognosis in cytogeneti-
cally normal AML with NPM1
þ/FLT3
  molecular proﬁle
17,28,29
and better prognosis in FLT3
þ AML.
27 In some
17 but not other
30
studies, the mutant IDH2 was associated with unfavorable
prognosis in cytogenetically normal AML,
17 whereas a more
recent study suggested that the mutant IDH2R140 was prognos-
tically more favorable than the mutant IDH2R172.
31
Unlike the case with AML, there is limited information on the
prognostic impact of IDH mutations in chronic myeloid
neoplasms, including MDS
19 and MPN.
8 We recently reported
on IDH1 and IDH2 mutational frequencies among 1473 patients
with BCR-ABL1-negative MPN:
8 0.8% in essential thrombo-
cythemia, 1.9% in polycythemia vera, 4.1% in PMF, 1% in
post-essential thrombocythemia/polycythemia vera MF, 0% in
blast-phase essential thrombocythemia, 25% in blast-phase
polycythemia vera and 25% in blast-phase PMF. The particular
study included only 111 patients with chronic-phase PMF and
complete clinical information; therefore, detailed prognostic
analysis was limited, especially in terms of clinically relevant
mutation interactions. In the current study, we examined the
phenotypic and prognostic effects of IDH1 and IDH2 mutations
among 301 patients with chronic-phase PMF, in the context of
other MPN-associated mutations.
Materials and methods
This study was approved by the Mayo Clinic Institutional Review
Board. All patients provided informed written consent for study
sample collection and permission for use in research. Study
eligibility criteria included availability of bone marrow histology
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www.nature.com/leuand cytogenetic information at the time of referral to the Mayo
Clinic. The diagnoses of PMF and leukemic transformation were
according to the World Health Organization criteria.
32 Patients
with blast-phase disease at the time of their referral to the Mayo
Clinic were excluded from the study because one of the objectives
of the study was to assess mutation impact on leukemic
transformation. Unfavorable karyotype designation and DIPSS-
plus (Dynamic International Prognostic Scoring System-plus) risk
categorization were as described previously.
33,34 All study patients
were fully characterized for karyotype, JAK2 and MPL mutational
status and DIPSS-plus risk category.
DNA from bone marrow or peripheral blood was extracted
using conventional methods. MPL and JAK2 mutation
analyses were performed according to previously published
methods.
35–38 IDH1 and IDH2 mutations were analyzed by
direct sequencing and/or high-resolution melting assay. Direct
sequencing for IDH1 exon 4 mutations was performed using
the following primer sequences: sense, 50-CGGTCTTC
AGAGAAGCCATT-30 and anti-sense, 50-CACATTATTGCCAA
CATGAC-30.
18 IDH2 exon 4 was ampliﬁed using sense,
50-CCACTATTATCTCTGTCCTC-30 and anti-sense, 50-GCTAGG
CGAGGAGCTCCAGT-30.
19 Both reactions were performed in
25ml volume containing 100ng of DNA, 0.25Units Taq
polymerase, 0.3mM each of dATP, dCTP, dGTP and dTTP,
5mlo fa1 0  PCR Buffer (Roche Diagnostics, Indianapolis, IN,
USA) and 0.2mM each of sense and anti-sense primers. The
reaction was denatured at 941C for 3min, followed by 35 cycles
of denaturing at 941C for 30s, annealing at 571C for 30s and
extension at 721C for 40s. After a ﬁnal extension at 721C for
2min, the products were conﬁrmed by 1.3% agarose gel and
puriﬁed using Qiagen’s PCR quick puriﬁcation kit (Qiagen,
Santa Clarita, CA, USA). The product was sequenced using the
ABI PRISM 3730xl analyzer (Applied Biosystems Inc., Foster
City, CA, USA) to screen for the presence of mutations.
High-resolution melting was performed using the LightCycler
480 Real-Time PCR system (Roche Diagnostics), using the above-
mentioned primers for IDH1 mutations (R130) and the following
primers for IDH2 mutations (R140 and R172): R140 sense, 50-G
CTGAAGAAGATGTGGAA-30 and anti-sense, 50-TGATGGGCT
CCCGGAAGA-30; R172 sense, 50-CCAAGCCCATCACCATTG-30
and anti-sense, 50-CCCAGGTCAGTGGATCCC-30.
All statistical analyses considered clinical and laboratory
parameters obtained at the time of ﬁrst referral to the Mayo
Clinic, which in most instances coincided with the time of bone
marrow biopsy at the Mayo Clinic and study sample collection.
Differences in the distribution of continuous variables between
categories were analyzed by either the Mann–Whitney (for
comparison of two groups) or the Kruskal–Wallis (comparison of
three or more groups) test. Patient groups with nominal variables
were compared by the w
2-test. Overall survival (OS) was
calculated from the date of ﬁrst referral to the date of death
(uncensored) or last contact (censored). Leukemia-free survival
(LFS) was calculated from the date of ﬁrst referral to the date of
leukemic transformation (uncensored) or death/last contact
(censored). OS and LFS curves were prepared by the Kaplan–
Meier method and compared by the log-rank test. Cox’s
proportional hazard regression model was used for multi-
variable analysis. P-values ol0.05 were considered signiﬁcant.
The Stat View (SAS Institute, Cary, NC, USA) statistical package
was used for all calculations.
Results
A total of 301 consecutive patients with PMF were included in
this study. The median age at the time of study was 63 years
(range, 14–82) and 65% were males. DIPSS-plus risk distribution
was 11% low, 16% intermediate-1, 36% intermediate-2 and
37% high. Other clinical and laboratory characteristics at the
time of Mayo Clinic referral are outlined in Table 1; 40 (13%)
patients had received cytoreductive therapy at the time of their
ﬁrst referral at our institution. The study population included
178 patients who were evaluated at or near the time of their
diagnosis and their presenting characteristics are separately
outlined in Table 2.
The mutant IDH was detected in 12 patients (4%): 7 IDH2
(5 R140Q, 1 R140W and 1 R172G) and 5 IDH1 (3 R132S and
2 R132C). MPL exon 10 was mutated in 18 patients (6.3%) and
constituted W515L in 14 patients, W515K in 3 and a novel
frameshift mutation in 1 patient. JAK2V617F was detected in
169 (56%) patients. Six patients displayed both JAK2V617F and
IDH mutations (IDH2R140Q in two patients, IDH2R140W in
one and IDH1R132S in three); JAK2V617F allele burdens in
these six patients with concomitant mutant IDH were 1, 7, 22,
27, 30 and 96%, respectively. One patient displayed both
IDHR140Q and MPLW515R. In all, 107 (36%) patients were
negative for all three mutations (that is, JAK2V617F, MPL exon
10 and IDH1/2).
The 12 IDH-mutated patients, with or without concomitant
JAK2V617F, were clinically compared with patients belonging
to the 3 other molecular subgroups: mutated for JAK2 only
(n¼164), mutated for MPL only (n¼18) and unmutated for all
three (n¼107). As can be seen in Tables 1 and 2, the four
molecular subgroups were remarkably similar in their pheno-
type with few exceptions; IDH-mutated patients were signiﬁ-
cantly older than those with no mutations (P¼0.04), whereas
age distribution was similar between patients with mutant
IDH, MPL or JAK2. At the time of this writing, 192 (64%) deaths
and 36 (12%) leukemic transformations were documented. The
median follow-up time for living patients was 68 months (range
12–296). Treatment over the course of the disease was primarily
with conventional drugs, and a total of 53 therapeutic
splenectomies and 24 transplants were documented.
In univariate analysis, IDH-mutated patients lived shorter than
did those with JAK2 (P¼0.03), MPL (P¼0.047) or no mutations
(P¼0.0009). The OS data for the four molecular subgroups are
shown in Figure 1. IDH-mutated patients also showed sig-
niﬁcantly shorter LFS, compared with those with JAK2
(P¼0.0008), MPL (P¼0.02) or no mutations (P¼0.001), as
shown in Figure 2. LFS was similar between patients with no
mutations and those with either MPL (P¼0.47) or JAK2
(P¼0.99). The OS of patients with no mutations was signiﬁ-
cantly longer than those with JAK2V617F (P¼0.01), but not
than those with MPL mutations (P¼0.41). After accounting for
age, the OS difference between patients with JAK2V617F and no
mutations became insigniﬁcant (P¼0.40), whereas the presence
of the mutant IDH remained a signiﬁcant disadvantage for both
OS (P¼0.04) and LFS (P¼0.005).
Multivariable analysis of OS that included risk categorization
per DIPSS-plus
33 conﬁrmed the independent prognostic rele-
vance of the mutant IDH (P¼0.03): hazard ratio (HR) for
patients with no mutations¼0.39, 95% conﬁdence interval
(95% CI) 0.2–0.75; HR for JAK2-mutated patients¼0.50, 95%
CI, 0.27–0.95; HR for MPL-mutated patients¼0.53, 95% CI,
0.23–1.2. A similar analysis for LFS that included risk factors for
leukemic transformation (that is, unfavorable karyotype and
platelet count o100 10
9/l) as covariates also conﬁrmed the
prognostic relevance of the mutant IDH (P¼0.003): HR for
patients with no mutations¼0.16; 95% CI, 0.06–0.46; HR
for JAK2-mutated patients¼0.18; 95% CI, 0.06–0.48; HR for
MPL-mutated patients¼0.09; 95% CI, 0.01–0.76).
33 Further
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Leukemiaanalysis disclosed that the negative OS (Figure 3) and LFS
(Figure 4) effect of the mutant IDH was most pronounced in the
presence (P¼0.0002 and Po0.0001, respectively) as opposed
to the absence (P¼0.34 and P¼0.64, respectively) of con-
comitant JAK2V617F expression. Analysis of paired samples
obtained during the chronic and blast phases of the disease was
possible in two IDH-mutated patients and showed the presence
of both IDH and JAK2 mutations at both time points.
Discussion
The most feared disease complication in MPN is leukemic
transformation.
39 In PMF, risk factors for leukemic progression
include unfavorable karyotype,
3 thrombocytopenia (platelet
count o100 10
9/l) and X3% circulating blasts;
33,40 the
10-year incidence of AML was estimated at 12% in the absence
of unfavorable karyotype and thrombocytopenia and 31% in the
presence of either one of the two risk factors.
33 Prognosis in
post-PMF AML is dismal with a median survival of o3 months
and is not favorably affected by conventional chemotherapy.
39
The discovery of JAK2V617F in the majority of patients with
PMF raised hopes of better outcome with effective molecularly
targeted therapy.
41 However, it has since been realized that the
presence or absence of JAK2V617F in PMF did not affect
leukemic transformation
35 and that leukemic blasts in JAK2-
mutated patients who develop AML did not necessarily express
the mutation.
42 These observations suggest that JAK2V617F
is neither necessary nor sufﬁcient for leukemic progression in
PMF.
This study suggests that the presence of the mutant IDH
signiﬁes an increased risk of leukemic transformation in PMF
and also raises the intriguing possibility of leukemogenic
collaboration between the mutant IDH and JAK2V617F;
4 (67%) of 6 patients with concomitant IDH and JAK2 mutations
developed AML as opposed to only 1 (17%) of 6 IDH-mutated
patients without concomitant JAK2V617F, 1 (6%) of 18 with
MPL mutations, 17 (10%) of 164 with only JAK2 mutation and
13 (12%) of 107 patients with no mutations (Po0.0001;
Figure 4). A similar clinical observation was made in a recent
report that showed an inferior LFS in IDH-mutated myeloid
malignancies with isolated del(5q);
43 in the particular study, two
of six patients with IDH mutations also carried JAK2V617F and
both had transformed into AML, whereas only two of the
remaining four IDH-mutated patients without concomitant
JAK2V617F had transformed into AML.
43 The possibility that
the mutant IDH collaborates with other oncogenes is further
supported by a recent report in which the mutant IDH enhanced
growth and mitogen-activated protein kinase and signal
transducer and activator of transcription-3 signaling in BRAF-
mutated melanoma cells.
44
Currently known mutations in PMF are believed to represent
late genetic events derived from an ancestral abnormal clone the
genetic make up of which remains elusive. The fact that many of
these mutations are infrequent and lack disease speciﬁcity
further undermines their pathogenetic contribution to disease
initiation.
4 On the other hand, the absence of mutual exclusivity
Table 1 Comparison of clinical characteristics of patients with primary myeloﬁbrosis stratiﬁed by the presence or absence of IDH, MPL
and JAK2 mutations
Variables All patients
(n¼301)
IDH
mutated
(n¼12)
MPL
mutated
(n¼18)
JAK2
mutated
(n¼164)
IDH/MPL/JAK2
unmutated
(n¼107)
P-value
Age (years); median (range) 63 (14–82) 66 (50–74) 62 (35–82) 65 (28–81) 58 (14–79) 0.0002
Age 465 years; n (%) 96 (32%) 6 (50%) 6 (33%) 77 (47%) 30 (28%) 0.02
Males (%) 197 (65%) 7 (58%) 11 (61%) 105 (64%) 74 (69%) 0.75
Hemoglobin, g/dl; median (range) 10 (6–15) 11 (7–15) 10 (6–14) 10 (7–15) 10 (6–14) 0.97
Leukocyte count,  10
9/l; median (range) 9 (1–176) 9 (4–48) 11 (4–50) 10 (1–176) 7 (1–147) 0.11
Platelet count,  10
9/l; median (range) 222 (11–1493) 141 (66–410) 128 (14–662) 218 (11–984) 257 (13–1493) 0.06
DIPSS-plus risk group (%)
Low 34 (11%) 0 4 (22%) 18 (11%) 12 (11%)
Intermediate-1 47 (16%) 2 (16%) 2 (11%) 19 (12%) 24 (22%)
Intermediate-2 109 (36%) 5 (42%) 3 (17%) 60 (37%) 41 (38%) 0.11
High 111 (37%) 5 (42%) 9 (50%) 67 (41%) 30 (28%)
Constitutional symptoms; n (%) 115 (38%) 5 (42%) 4 (22%) 69 (42%) 37 (35%) 0.30
Circulating blasts X1%; n (%) 190 (63%) 10 (83%) 11 (61%) 101 (62%) 68 (64%) 0.50
Hemoglobin o10g/dl; n (%) 151(50%) 5 (42%) 10 (56%) 88 (54%) 48 (45%) 0.46
Leukocytes 425 10
9/l; n (%) 52 (17%) 2 (17%) 4 (22%) 33 (20%) 13 (12%) 0.36
Platelets o100 10
9/l; n (%) 73 (24%) 3 (25%) 8 (44%) 35 (21%) 27 (25%) 0.19
Leukocytes o4 10
9/l; n (%) 46 (15%) 1 (8%) 1 (6%) 24 (15%) 20 (19%) 0.43
Palpable spleen 410cm; n (%) 109 (36%) 2 (17%) 5 (28%) 67 (41%) 35 (33%) 0.20
Splenectomy; n (%) 53 (18%) 2 (17%) 4 (22%) 28 (17%) 19 (18%) 0.96
Cytogenetic categories
Normal 181 (60%) 9 (75%) 12 (67%) 92 (56%) 68 (64%)
Favorable 89 (30%) 2 (17%) 6 (33%) 53 (32%) 28 (26%) 0.55
Unfavorable 31 (10%) 1 (8%) 0 (0%) 19 (12%) 11 (10%)
Transplanted; n (%) 24 (8%) 0 (0%) 2 (11%) 10 (6%) 13 (12%) 0.31
Deaths; n (%) 192 (64%) 11 (92%) 12 (67%) 109 (66%) 58 (54%) 0.04
Leukemic transformations; n (%) 36 (12%) 5 (42%) 1 (6%) 17 (11%) 13 (12%) 0.01
Abbreviation: DIPSS-plus, Dynamic International Prognostic Scoring System-Plus.
Bold values indicate signiﬁcant differences.
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Leukemiaand the higher prevalence of some MPN-associated mutations
(for example, IDH,
6 LNK,
7 IKZF1
45 and TP53
46 mutations) in
blast-phase, as opposed to chronic-phase, disease suggests
possible pathogenetic contribution to leukemic transformation.
The observations from this study suggest one possibility in which
mutations with non-redundant functional consequences colla-
borate to amplify the development of AML. Alternatively, the
presence of mutations of interest (such as the mutant IDH)i n
at-risk patients might simply constitute a marker of genomic
instability associated with impending leukemic transformation.
A third possibility considers the distribution of speciﬁc muta-
tions in independent clones that arise from a common ancestral
clone that is susceptible to both emergence of mutations of
interest and leukemic transformation.
47
The prognostic impact of IDH mutations in AML has been
studied extensively.
16,17,23–30 In contrast, very few studies have
looked into this matter in chronic myeloid malignancies. Both
IDH1 and IDH2 mutations occur in MDS, although some
studies
19 have reported a preponderance of IDH1 mutations,
whereas others have shown the opposite.
20 In the current PMF
Table 2 Comparison of clinical characteristics of patients with primary myeloﬁbrosis, who were evaluated within 1 year of diagnosis, stratiﬁed
by the presence or absence of IDH, MPL and JAK2 mutations
Variables All patients
(n¼178)
IDH
mutated
(n¼10)
MPL
mutated
(n¼9)
JAK2
mutated
(n¼96)
IDH/MPL/JAK2
un-mutated
(n¼63)
P-value
Age (years); median (range) 63 (14–81) 66 (50–74) 60 (35–66) 65 (28–81) 58 (14–79) 0.005
Age 465 years; n (%) 70 (39%) 5 (50%) 1 (11%) 48 (50%) 16 (25%) 0.004
Males (%) 116 (65%) 7 (70%) 7 (80%) 63 (66%) 39 (62%) 0.79
Hemoglobin, g/dl; median (range) 10 (6–15) 11 (7–15) 10 (6–14) 10 (7–15) 11 (6–14) 0.50
Leukocyte count,  10
9/l; median
(range)
8 (1–147) 10 (4–48) 11 (4–50) 9 (1–99) 7 (2–147) 0.15
Platelet count,  10
9/l; median
(range)
253 (12–1493) 159 (79–410) 146 (31–662) 245 (12–984) 316 (14–1493) 0.13
DIPSS-plus risk group (%)
Low 25 (14%) 0 2 (22%) 13 (14%) 10 (16%) 0.60
Intermediate-1 36 (20%) 2 (20%) 1 (11%) 15 (16%) 18 (29%)
Intermediate-2 62 (35%) 4 (40%) 3 (33%) 35 (36%) 20 (32%)
High 55(31%) 4 (40%) 3 (33%) 33 (34%) 15 (24%)
Constitutional symptoms; n (%) 65 (37%) 4 (40%) 2 (22%) 38 (40%) 21 (33%) 0.68
Circulating blasts X1%; n (%) 101 (57%) 8 (80%) 5 (56%) 54 (56%) 34(53%) 0.49
Hemoglobin o10g/dl; n (%) 77 (43%) 4 (40%) 6 (67%) 47 (49%) 20 (32%) 0.08
Leukocytes 425 10
9/l; n (%) 26 (15%) 2 (20%) 2 (22%) 14 (15%) 8 (13%) 0.84
Platelets o100 10
9/l; n (%) 36 (20%) 1 (10%) 4 (44%) 17 (18%) 14 (22%) 0.22
Leukocytes o4 10
9/l; n (%) 27 (15%) 1 (10%) 1 (11%) 12 (13%) 13 (21%) 0.51
Palpable spleen 410cm; n (%) 44 (25%) 2 (20%) 2 (22%) 28 (29%) 12 (19%) 0.45
Splenectomy; n (%) 24 (13%) 1 (10%) 3 (33%) 12 (13%) 8 (13%) 0.35
Cytogenetic categories
Normal 116 (65%) 7 (70%) 6 (67%) 58 (60%) 45 (71%) 0.75
Favorable 48 (27%) 2 (20%) 3 (33%) 30 (31%) 13 (21%)
Unfavorable 14 (8%) 1 (10%) 0 (0%) 8 (8%) 5 (8%)
Transplanted; n (%) 15 (8%) 0 (0%) 2 (22%) 5 (5%) 8 (13%) 0.12
Deaths; n (%) 107 (60%) 9 (90%) 6 (67%) 59 (61%) 32 (51%) 0.09
Leukemic transformations; n (%) 22 (12%) 4 (40%) 1 (11%) 13 (14%) 4 (6%) 0.03
Abbreviation: DIPSS-plus, Dynamic International Prognostic Scoring System-Plus.
Bold values indicate signiﬁcant differences.
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Figure 1 Overall survival data for 301 patients with primary
myeloﬁbrosis stratiﬁed by the presence or absence of IDH, MPL and
JAK2 mutations.
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Figure 2 Leukemia-free survival data for 301 patients with primary
myeloﬁbrosis stratiﬁed by the presence or absence of IDH, MPL and
JAK2 mutations.
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Leukemiastudy, 7 of the 12 IDH mutations involved IDH2. In MDS and
other myeloid neoplasms associated with sole del(5q), the
presence of mutant IDH has been associated with inferior OS
and LFS.
19,21,43 It is noteworthy that the MDS study showing a
detrimental prognostic effect of the mutant IDH involved only
IDH1 mutations.
19 In this study, there was no evidence to
suggest that IDH1 and IDH2 mutations were prognostically
different (data not shown). Regardless, the number of cases with
IDH mutations in this study (n¼12) was too small to accurately
determine the individual prognostic contribution of IDH1 vs
IDH2 mutations in PMF.
JAK2V617F in PMF and other MPN is associated with
advanced age.
48 This study suggests that IDH mutations in
PMF also cluster with older age. A similar observation has been
made in AML as well
28 and underscores the importance of
accounting for age in evaluating the prognostic signiﬁcance of
IDH mutations. Another characteristic feature of IDH-mutated
PMF in this study was the relative paucity of abnormal or
unfavorable karyotype. This particular observation has also been
noted in the context of AML, MDS, MDS/MPN and post-MDS/
MPN AML
8,18,20 and suggests that IDH mutations are not simply
markers of genomic instability.
Our clinical observations underscore the potential relevance
of looking for other mutations or epigenetic abnormalities that
functionally mimic the mutant IDH,i nJAK2-mutated PMF.
13
It would also be interesting to examine the mutant IDH-induced
phenotypic modiﬁcations of JAK2V617F mouse models.
Whether therapeutic targeting of the mutant IDH or interfering
with the production/function of its ‘oncogenic’ metabolite (that
is, 2-hydroxyglutarate) would favorably affect leukemic progres-
sion in PMF remains to be seen.
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